NAD+ Injection Dosage Guide (Subcutaneous): Complete Protocol for Safe Administration

Medically reviewed by the BHRC Clinical Team — Beverly Hills Rejuvenation Center · Published / Reviewed July 24, 2026 · Written by Sam Brooks

Educational information only — not medical advice. NAD+ is not an FDA-approved drug for any indication, and compounded injectable NAD+ has not been reviewed or approved by the FDA. The doses discussed below are drawn from clinical use and physician-directed compounded protocols and are provided for education, not as self-administration instructions. Injectable NAD+ therapy at Beverly Hills Rejuvenation Center is always physician-prescribed and supervised. Do not obtain or inject NAD+ without a qualified prescriber. Most of the strongest human evidence in this space is for oral NAD+ precursors (NMN and NR), not injectable NAD+.

Quick NAD+ Injection Dosing Summary

In physician-supervised practice, subcutaneous NAD+ is usually started low — around 20–50 mg per injection — and titrated up toward roughly 50–100 mg, given 1–3 times per week, because nausea and flushing are dose- and rate-dependent. Some protocols use a short loading phase of roughly 100–200 mg daily for 7–10 days, then step down to a weekly maintenance dose of about 50–100 mg. NAD+ is injected into the fat just under the skin of the abdomen, thigh, or back of the upper arm. Milligram-to-milliliter math depends entirely on the vial’s concentration: at 200 mg/mL, 0.1 mL delivers about 20 mg and 0.5 mL delivers about 100 mg. All of this is provider-directed; NAD+ is not FDA-approved.

Schedule a consultation to discuss whether a physician-supervised NAD+ protocol is appropriate for you.

What Is NAD+ (and Why Inject It Subcutaneously)?

NAD+ (nicotinamide adenine dinucleotide) is one of the most fundamental molecules in human biology — a coenzyme present in every living cell that is essential for turning food into cellular energy. Injectable NAD+ has become popular in wellness and longevity clinics, and the subcutaneous route in particular is marketed as a more convenient, lower-intensity alternative to the long IV infusions that dominate the category. Before discussing dose, it is worth being precise about what NAD+ is, what it does, and what the honest evidence actually supports.

NAD+ Is a Coenzyme, Not a Peptide

Although NAD+ is frequently grouped with peptide therapies in clinic menus, it is not a peptide. It is a dinucleotide — two nucleotides joined through their phosphate groups — that acts as an electron carrier in metabolism. This distinction matters for accuracy and for regulation: NAD+ is handled by compounding pharmacies and the FDA differently than the growth-hormone-axis peptides people often mention in the same breath. We flag it here because a trustworthy guide should not blur the chemistry.

How NAD+ Works in the Body

NAD+ shuttles electrons in the reactions that produce ATP, the cell’s energy currency, and it is a required cofactor for enzymes that influence DNA repair signaling and cellular stress responses — most notably the sirtuins and the PARP family of enzymes. Because so many of these processes touch metabolism, energy, and cellular maintenance, NAD+ has become a magnet for anti-aging interest. That interest, however, has consistently run ahead of the human outcome data, a gap this guide keeps in view throughout.

Why NAD+ Declines and Why People Supplement It

Tissue NAD+ concentrations in skin, blood, muscle, liver, and brain tend to decline with age, and this observed decline is the central rationale offered for supplementation: the idea that “topping up” NAD+ might support cellular energy and resilience. It is important to separate the observation from the conclusion. A biomarker falling with age does not prove that raising it back up reverses aging or treats any disease — it is a hypothesis that is still being tested, mostly with oral precursors rather than injections.

Subcutaneous NAD+ vs. Oral NMN and NR Precursors

Much of the confusion in this space comes from conflating injectable NAD+ with its oral precursors. Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are small molecules the body uses to build NAD+; they are taken orally and have been the subject of most of the well-controlled human trials. Injectable NAD+ delivers the finished coenzyme directly, bypassing digestion, but it has far less rigorous human trial support than the precursors do. When a marketing page cites “NAD+ research,” it is very often citing NMN or NR studies. We separate the two deliberately below.

What the Research Actually Shows (Honest Benefits Framing)

NAD+ injections are promoted for energy, focus, metabolic health, recovery, and “healthy aging.” Understanding which of those claims rest on human evidence — and which rest on mechanism, animal data, or extrapolation from oral precursors — is essential before any dose conversation. Nothing here should be read as a treatment or cure claim.

Human Evidence Is Mostly for Oral Precursors

The best-controlled human data in this field involve oral NR and NMN. A randomized, placebo-controlled crossover trial by Martens and colleagues found that 1,000 mg/day of nicotinamide riboside for six weeks was well tolerated and effectively raised NAD+ levels in healthy middle-aged and older adults, with a suggestion of reduced blood pressure in some participants. Reviews of NMN report that it reliably boosts circulating NAD+ and is generally well tolerated, with some metabolic signals. Crucially, these are precursor studies — not studies of subcutaneous NAD+ injections — and even they show that raising NAD+ is easier to demonstrate than proving it changes hard clinical outcomes.

Metabolic and Cellular-Energy Research

NAD+ biology is genuinely central to metabolism, and precursor trials have reported modest effects such as small improvements in blood lipids in some overweight participants. But systematic reviews have also found that many clinically meaningful endpoints — body composition, insulin sensitivity, physical performance — were not consistently improved, and a few studies even flagged unfavorable metabolic signals. The honest summary is “biologically plausible, human outcomes mixed and modest,” not “proven metabolic therapy.”

Cognitive, Energy, and Subjective “Feel” Reports

Many patients pursue NAD+ injections for subjective energy, mental clarity, or a sense of recovery. These reports are real to the people who have them, but they come largely from open-label clinic use and self-report, where expectation effects are strong and placebo response is well documented. Controlled evidence that injectable NAD+ improves cognition or energy in healthy adults is limited. A responsible clinic frames these as possible, individual, and unproven — not guaranteed.

What NAD+ Injections Are NOT Proven To Do

Several claims carry the highest regulatory and ethical risk and are not supported for injectable NAD+: reversing aging, repairing DNA to prevent disease, curing neurodegenerative conditions, or treating addiction and substance-use withdrawal. Addiction-treatment marketing in particular has drawn regulatory scrutiny. BHRC does not present NAD+ as a treatment for any disease. Where benefits are discussed, the framing is strictly “may support” or “early research suggests,” and the strongest data belong to oral precursors, not injections.

NAD+ Injection Dosing Protocols (Loading vs. Maintenance)

There is no FDA-established dose for injectable NAD+ because no pivotal human trial has defined one. The protocols below are drawn from physician-supervised compounded use and are presented as reference education, not a prescription. The single most important dosing principle is that NAD+’s tolerability is tied to both dose and injection rate, which is why nearly every protocol starts low and increases slowly.

Standard Subcutaneous Dosing Ranges

Most subcutaneous protocols begin at roughly 20–50 mg per injection and titrate upward over the first few weeks toward about 50–100 mg, given one to three times per week. Some clinics reference a wider per-day window of 50–200 mg for experienced patients, but higher single doses raise the likelihood of nausea and flushing and are approached cautiously. Because subcutaneous absorption is gradual, SubQ dosing tends to be gentler than a rapid IV push of the same amount.

Loading Phase Protocol

Some providers use a short, front-loaded phase to raise NAD+ availability more quickly at the start of therapy. A commonly cited loading pattern is roughly 100–200 mg daily for about 7–10 days, or 2–3 injections per week at the higher end of the range for the first several weeks, before stepping down. Loading is optional and not universal; it increases exposure and therefore the chance of transient side effects, so it is only appropriate under supervision and after tolerability at lower doses has been confirmed.

Maintenance Phase Protocol

After the initial or loading phase, most patients settle into a maintenance dose of about 50–100 mg given weekly, or 1–2 times per week. The maintenance goal is to sustain whatever benefit the patient and provider have identified while minimizing injection frequency and side effects. Maintenance dose and cadence are individualized: some patients do well on a single weekly injection, others prefer twice weekly at a lower per-dose amount.

Beginner, Intermediate, and Advanced Dosing Tiers

NAD+ Dosage Chart by Goal

These groupings are illustrative. NAD+ is not a proven treatment for any specific condition, so “goal” here means the pattern of use a provider might choose, not a promised outcome.

NAD+ Dosage Chart by Body Weight

Unlike some peptides, subcutaneous NAD+ is not usually dosed by a strict mg/kg formula in clinical practice — tolerability (especially nausea threshold) tends to drive the dose more than body weight does. That said, larger individuals sometimes tolerate and are prescribed the higher end of the range. The table below is a loose orientation, not a calculation to self-apply.

Notice that even at higher body weights, the recommended dose does not climb indefinitely — the nausea ceiling, not weight, is usually the limiting factor. Your prescriber individualizes the dose regardless of what a weight chart suggests.

How Much NAD+ Per Week and Why Frequency Matters

A common weekly maintenance total lands around 50–200 mg spread across one to three injections. Splitting the weekly amount into smaller, more frequent doses is often better tolerated than one large injection, because each individual dose stays under the nausea threshold. This is the practical reason “take it all at once, less often” is discouraged: side-effect risk rises steeply with a single large dose, while a divided schedule keeps each exposure gentle.

Why Titration Matters More for NAD+ Than for Most Peptides

NAD+ is unusual in how strongly its side effects track with dose and injection speed. Nausea is uncommon below about 200 mg and becomes more likely above roughly 300 mg, and flushing, warmth, and lightheadedness follow the same pattern. Starting low, injecting slowly, and increasing only when a dose has been comfortable is not just conservative — it is the mechanism by which most patients avoid the very side effects NAD+ is known for. Titration is the protocol, not an optional courtesy.

Subcutaneous vs. IV vs. Intramuscular NAD+ Dosage

One of the most under-explained topics in this category is how the route of administration changes dosing, tolerability, and convenience. Patients researching “NAD+ subcutaneous vs IV dosage” deserve a straight comparison.

Subcutaneous (SubQ) NAD+

Subcutaneous injection places NAD+ into the fat layer beneath the skin, where it absorbs gradually. This slower absorption is exactly why SubQ doses (typically 20–100 mg per injection) are far smaller than IV doses and why SubQ is generally described as gentler on the stomach and cardiovascular system. It is also the route best suited to at-home, physician-directed self-administration because it uses a small insulin syringe rather than an infusion line.

Intravenous (IV) NAD+

IV NAD+ delivers the coenzyme directly into the bloodstream, usually in much larger amounts (commonly several hundred milligrams up to 500–1,000 mg per session) infused slowly over one to several hours. The infusion is deliberately slow because a fast IV rate is the classic trigger for nausea, flushing, chest tightness, a racing heart, and a drop in blood pressure. IV sessions are time-intensive and clinic-based, which is a major reason SubQ has grown as a lower-friction alternative for maintenance.

Intramuscular (IM) NAD+

Intramuscular injection places NAD+ into muscle. IM is used less often for NAD+ than SubQ or IV; volumes are limited by what a muscle can comfortably hold, and it can be more uncomfortable at the injection site. When used, IM doses are broadly in the same modest per-injection range as SubQ. Route selection — SubQ, IM, or IV — is a clinical decision based on goals, tolerability, and convenience.

SubQ vs. IV Dosage Comparison

The key takeaway: SubQ and IV are not interchangeable at the same number. A 100 mg SubQ injection and a 500 mg IV drip are simply different protocols with different tolerability profiles, and only a provider should map one to the other.

NAD+ mg-to-mL Conversion and Syringe Math

Because compounded injectable NAD+ comes in different concentrations, the same milligram dose can be a different number of milliliters — and a different number of insulin-syringe units — depending on the vial. Getting this conversion right is a core safety point.

Understanding Concentration

Concentration is expressed in mg/mL — how many milligrams of NAD+ are dissolved in each milliliter of solution. Compounded NAD+ is commonly supplied at 100 mg/mL or 200 mg/mL, though other strengths exist. The formula that ties everything together is simple:

Volume (mL) = desired dose (mg) ÷ concentration (mg/mL), and on a U-100 insulin syringe, units = mL × 100.

NAD+ mg-to-mL Conversion Table

The tables below assume a standard U-100 insulin syringe, where 100 units = 1.0 mL. “Units” refers to the marks on that syringe, which measure volume, not milligrams.

Notice how the same 100 mg dose is 1.0 mL (100 units) at 100 mg/mL but only 0.5 mL (50 units) at 200 mg/mL. This is why you must always read the concentration on your specific vial’s label rather than memorizing a unit number.

Worked Syringe Examples

• Example 1 — 50 mg from a 100 mg/mL vial: 50 ÷ 100 = 0.50 mL = 50 units.
• Example 2 — 50 mg from a 200 mg/mL vial: 50 ÷ 200 = 0.25 mL = 25 units.
• Example 3 — 20 mg starter dose from a 200 mg/mL vial: 20 ÷ 200 = 0.10 mL = 10 units.
• Example 4 — 100 mg from a 100 mg/mL vial: 100 ÷ 100 = 1.00 mL = 100 units (a full standard insulin syringe).

The general rule: units = (desired mg ÷ concentration in mg/mL) × 100. Your prescribing clinician should confirm the concentration and the math for every dose before any injection.

Common mg-to-mL Mistakes to Avoid

• Confusing units with milligrams. Units are a volume mark, not a mass. The conversion always depends on concentration.
• Assuming all vials are the same strength. A dose that is 50 units at 100 mg/mL is only 25 units at 200 mg/mL. Re-check the label every time a new vial is dispensed.
• Overfilling the syringe. If a dose exceeds 100 units on a 1 mL insulin syringe, a more concentrated vial or a larger syringe is needed — confirm with the pharmacy.

How to Prepare NAD+ for Injection (Reconstitution)

How NAD+ is prepared depends on how the compounding pharmacy supplies it. This section explains the process for education; in practice, preparation is handled by the pharmacy or trained clinical staff, and this is not an instruction to compound gray-market product.

Pre-Mixed Solution vs. Lyophilized Powder

Because NAD+ is chemically fragile, many compounding pharmacies dispense it as a ready-to-use sterile solution at a set concentration (for example, 100 mg/mL or 200 mg/mL), so no mixing is required — you simply draw the prescribed volume. Others supply it as a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water before use. Always follow the specific pharmacy’s labeling; if your NAD+ arrives as a solution, skip the reconstitution steps entirely.

Bacteriostatic Water and Why It Matters

When reconstitution is required, it should use bacteriostatic water — sterile water containing 0.9% benzyl alcohol as a preservative. The preservative inhibits microbial growth, which is what allows a multi-dose vial to be used over a period of days to weeks. Plain sterile water has no preservative and is intended for single use. Benzyl alcohol is also why bacteriostatic water is generally avoided in neonates and, out of caution, in pregnancy — one more reason NAD+ belongs in supervised care.

Step-by-Step Reconstitution (If Supplied as Powder)

1. Let the sealed vial and bacteriostatic water reach room temperature. Wash hands and work on a clean surface.
2. Wipe both rubber stoppers with fresh alcohol swabs.
3. Draw the pharmacy-specified volume of bacteriostatic water into a sterile syringe.
4. Insert the needle at an angle and let the water run slowly down the inside wall of the vial — never blast it directly onto the powder.
5. Swirl gently; do not shake. Shaking can degrade the molecule and cause foaming. Allow it to dissolve into a clear solution.
6. Discard any solution that is cloudy, discolored, or contains particulate. Label the vial with concentration and date.
7. Store as directed — refrigerated (2–8 °C), protected from light.

Storage and Stability

NAD+ is notoriously unstable — it degrades with heat, light, moisture, and changes in pH, and the solid form is hygroscopic (readily absorbs water). This fragility is central to how the FDA has viewed it and is exactly why NAD+ should be kept refrigerated, shielded from light, and used within the pharmacy’s stated dating. Do not leave vials at room temperature for extended periods, and discard early if the solution changes color or clarity. When traveling, transport in an insulated cooler with a cold pack, keeping the vial cold but not frozen unless the pharmacy directs otherwise.

How to Inject NAD+ Subcutaneously at Home (Step by Step)

Subcutaneous NAD+ uses the same basic technique as insulin or other subcutaneous injections. The walkthrough below is educational; at BHRC, the clinical team teaches and supervises technique before any patient administers a dose at home.

Prescription and Medical-Supervision Gate

Before any of the following applies to you: injectable NAD+ requires a prescription and a supervising clinician. This is not a formality. Dose, concentration, injection rate, candidacy, and monitoring all depend on a medical evaluation, and gray-market vials carry real contamination and mislabeling risks. If you do not have a prescription and a provider, the correct next step is a consultation — not sourcing NAD+ online. Everything below assumes you are already in a supervised program and have been trained by your clinic.

Injection Site Selection (Abdomen, Thigh, Upper Arm)

• Abdomen — the most common site; stay at least 2 inches (about 5 cm) away from the navel.
• Outer/front thigh — a large, easy-to-reach area with ample subcutaneous fat.
• Back of the upper arm — where enough subcutaneous fat is present.
• Upper/outer buttock — an additional option for rotation.

Rotate sites with each injection to reduce irritation and lipohypertrophy (fatty lumps). Do not inject into skin that is bruised, tender, scarred, or inflamed.

Step-by-Step Subcutaneous Injection Technique

1. Wash hands; swab the chosen site with alcohol and let it dry completely (injecting into wet alcohol stings).
2. Draw the prescribed number of units; tap out air bubbles.
3. Pinch a fold of skin. Insert the short insulin needle at a 45–90° angle depending on body-fat thickness.
4. Depress the plunger slowly and steadily. With NAD+, a slow injection is the main way to blunt the transient stinging, warmth, or nausea some people feel.
5. Withdraw the needle, release the pinch, and apply light pressure with a clean swab. Do not rub vigorously.
6. Dispose of the needle in a proper sharps container — never reuse needles.

Reducing Nausea and Injection Discomfort

NAD+ has a reputation for a brief flushing or nauseated feeling, and technique makes a real difference. Inject slowly rather than fast; keep the dose within your titrated, tolerated range; make sure the solution is not ice-cold at the moment of injection; let the alcohol dry first; and use a fresh, sharp needle each time. When mild nausea or flushing does occur with a subcutaneous dose, it typically lasts only about 15–30 minutes and resolves on its own. Persistent, worsening, or infected-looking sites should always be reviewed by the care team.

Needle and Syringe Selection

Subcutaneous NAD+ is typically drawn and injected with a small-gauge, short insulin needle — commonly around 29–31 gauge and 5/16 to 1/2 inch (8–13 mm) long. A U-100 insulin syringe is standard because its unit markings make small-volume dosing precise. Use a new sterile needle for every injection; needles dull quickly, and reuse increases pain, infection risk, and tissue trauma. All sharps go into an approved container, never household trash.

Optimal Timing for NAD+ Injections

Timing for NAD+ is driven less by a specific biological window and more by tolerability and routine. There is no strong human trial establishing a “best” time of day.

Time of Day

Many patients prefer morning injections, both to fold the routine into the start of the day and because any transient flushing or lightheadedness then passes well before sleep. Some people report that NAD+ feels stimulating, which is another reason to avoid dosing right before bed. The practical rule is to pick a consistent time that fits your schedule and stick with it.

Injection Speed and the Nausea Connection

The most important “timing” variable for NAD+ is not the clock — it is how fast you inject. Because side effects are rate-dependent, a slow, unhurried injection is more comfortable than a fast one at the same dose. This mirrors the IV world, where infusions are deliberately slowed to keep patients comfortable.

Consistency and Spacing of Doses

For multi-day-per-week schedules, spacing doses evenly (for example, Monday/Thursday) helps keep exposure steady and side effects predictable. Consistency of routine matters more than chasing a perfect window, and your provider sets the cadence based on your protocol and tolerability.

NAD+ Cycle Length and Protocol Duration

NAD+ is typically used in a structured way — often a front-loaded start followed by ongoing maintenance — rather than at a fixed dose forever, both to gauge response and because long-term data on injectable NAD+ are limited.

Loading Then Maintenance Structure

A frequently used arc is a short loading phase (for example, higher-frequency dosing or a 7–10 day daily load), followed by a maintenance phase of weekly or twice-weekly injections. The maintenance phase can continue for as long as it is providing benefit and being tolerated, with periodic reassessment. Some patients instead skip loading and simply run a steady low-dose maintenance from the start.

How Long Until Effects Appear

Reported timelines vary widely and are subjective. Some patients describe changes in energy or clarity within the first week or two of a loading phase; others notice little, especially without attention to sleep, training, and nutrition. Because controlled evidence for injectable NAD+ is limited, these timelines should be treated as anecdotal, and a defined trial period with honest reassessment is the responsible approach.

Breaks and Reassessment

Building in reassessment points — rather than running a protocol indefinitely on autopilot — lets a clinician review whether NAD+ is actually delivering value for a given patient. If there is no meaningful benefit after a fair trial, continuing is hard to justify given the cost and the experimental status of the therapy. Off periods also let injection sites recover and give patients a clear decision point.

NAD+ Safety Profile and Potential Side Effects

Subcutaneous NAD+ is generally well tolerated at modest doses, with side effects that are mostly mild, transient, and tied to dose and injection rate. Long-term safety data for injectable NAD+ specifically are limited, which is one more reason for supervision.

Common and Mild Side Effects

• Injection-site reactions — redness, itching, a brief burning feeling, or a small bruise
• Nausea — dose-dependent; uncommon under ~200 mg, more likely above ~300 mg
• Flushing, warmth, or a “wave” sensation, usually within 10–20 minutes and passing within an hour
• Headache
• Dizziness or lightheadedness
• Transient fatigue or, in some people, a stimulated/energized feeling

With subcutaneous dosing, these effects tend to be milder than with a rapid IV push, because tissue absorption slows the delivery. Injecting slowly and staying within a titrated dose keeps most of them minimal.

Contraindications and Cautions

• Pregnancy and breastfeeding — avoid; no safety data, and bacteriostatic water’s benzyl alcohol is a further concern.
• Active cancer or a history of certain cancers — requires oncology input; NAD+ metabolism intersects with cell-signaling pathways, and the risk-benefit is uncertain.
• Significant cardiovascular disease — flushing/vasodilation and blood-pressure effects warrant caution, especially at higher doses or faster rates.
• Known hypersensitivity to NAD+ or to excipients such as benzyl alcohol.
• Anyone unable to obtain a physician-supervised, pharmacy-sourced product should not use NAD+ at all.

Drug and Supplement Interactions

Formal interaction studies for injectable NAD+ are lacking because it is not an FDA-approved drug. Patients should nonetheless review their full medication and supplement list with the prescriber — including blood-pressure medications (given NAD+’s vasodilatory, flushing-type effects) and any other agents that affect the cardiovascular system. The absence of formal interaction data is a reason for more caution, not less.

When to Seek Medical Attention

Most effects are mild and self-limiting, but some signs warrant prompt contact with a clinician or urgent care: symptoms of a significant allergic reaction (widespread rash, swelling of the face, lips, or tongue, difficulty breathing); chest pain, a pounding or irregular heartbeat, or fainting; a spreading, painful, or pus-producing injection-site infection; or any severe or persistent symptom. Because NAD+ is not an approved drug, err on the side of reporting anything unusual to the prescribing team.

The Gray-Market Sourcing Risk

A large share of real-world NAD+ risk has nothing to do with the molecule itself — it comes from unregulated “research-only” vials sold online with no guarantee of identity, purity, dose accuracy, or sterility. Given how unstable NAD+ is, an improperly stored or manufactured product may also have degraded. BHRC’s position is unambiguous: injectable NAD+ should only ever be used as a physician-prescribed, pharmacy-compounded product under supervision.

Schedule a consultation to review your health history and medications before considering any injectable NAD+ protocol.

Combining NAD+ with Other Therapies

NAD+ is frequently discussed alongside oral precursors and various peptides. Combining therapies multiplies both potential benefit and potential risk, and should only be designed by a clinician. The comparison matrix below outlines how injectable NAD+ differs from the options it is commonly mentioned with — it is educational, not a recommendation to combine them.

NAD+ vs. Precursors and Commonly Mentioned Options

NAD+ and Oral Precursors

Some patients use an oral NMN or NR supplement alongside a supervised injectable NAD+ protocol, on the logic that the precursors provide steady day-to-day support while injections front-load availability. This is a reasonable-sounding pairing, but there is no strong trial proving the combination outperforms either alone. If anything, the more robust human data favor the oral precursors, so a provider may reasonably suggest starting there.

NAD+ and Peptide Stacks

Because NAD+ shows up on the same clinic menus as growth-hormone-axis and metabolic peptides, patients often ask about stacking. Any such combination compounds variables and side-effect potential and must be designed and supervised by a physician. If you are exploring a recovery- or metabolism-oriented plan, our clinicians can explain the trade-offs — see, for example, our CJC-1295/Ipamorelin therapy page. Introduce one variable at a time so that any benefit or side effect can actually be attributed.

NAD+ Alongside Lifestyle Fundamentals

The most defensible “stack” for NAD+ is not another injectable at all — it is the fundamentals. Sleep, resistance and aerobic training, adequate protein, and a sensible caloric plan drive far more of the energy and metabolic outcomes people hope NAD+ will deliver. Layered on a poor foundation, any injectable is unlikely to impress.

Who Should Consider NAD+ Injection Therapy?

NAD+ is not for everyone, and at BHRC candidacy is determined by a physician after review of history, goals, and medications.

Potential Candidates

• Adults interested in a supervised, closely monitored trial of NAD+ for energy or general wellness who understand the evidence is early
• Patients who have already optimized sleep, training, and nutrition and want to explore an adjunct
• People who prefer the convenience of subcutaneous maintenance dosing over long IV infusions

Who Should Not Use NAD+

• Anyone pregnant, trying to conceive, or breastfeeding
• People with active cancer or significant cardiovascular disease without specialist clearance
• Anyone seeking NAD+ as a “treatment” for a diagnosed disease, addiction, or a neurodegenerative condition — it is not proven for these uses
• Anyone unwilling or unable to use a physician-prescribed, pharmacy-sourced product

The Consultation and Candidacy Process

A BHRC evaluation includes medical history, current medications, goals, and — where relevant — labs. Only after that review does a provider determine whether injectable NAD+, an oral precursor, or a different approach makes sense, and at what dose, concentration, and schedule. The consultation is also where realistic expectations, monitoring cadence, and stop criteria are set, so the decision to start (or not) is made with full information rather than marketing hype. To begin, schedule a consultation with our clinical team.

Monitoring Progress and Adjusting Protocols

Because injectable NAD+ is not a proven treatment with defined endpoints, structured self-monitoring and provider check-ins are what separate responsible use from guesswork.

What to Track

• Subjective energy, mental clarity, sleep quality, and recovery (with the caveat that these are placebo-prone)
• Tolerability — nausea, flushing, and injection-site reactions at each dose
• Where clinically indicated, relevant labs your provider selects (for example, metabolic markers)
• Adherence to the prescribed dose, concentration, and schedule

When and How to Adjust the Dose

Dose changes are made by the prescriber based on tolerability and response — for example, titrating upward only after a lower dose has been comfortable, or reducing frequency if side effects appear. Self-escalating dose or injection speed is discouraged: more is not reliably better with NAD+, and pushing the dose is the fastest way to provoke nausea and flushing.

Setting Realistic Expectations

NAD+ is not a guaranteed, felt-instantly therapy, and the honest evidence — strongest for oral precursors, limited for injections — should temper expectations. Framing a defined trial with clear metrics and a willingness to stop if the data do not support continuing is part of using an unproven therapy responsibly. A clinic that promises transformation or “reversed aging” is a red flag.

Is NAD+ FDA-Approved? Legal & Regulatory Status (2026)

As of July 24, 2026, NAD+ is not approved by the U.S. Food and Drug Administration for any indication. Injectable NAD+ used in clinics is a compounded preparation, and compounded NAD+ has not been reviewed or approved by the FDA. It should never be presented as an approved medication.

FDA Approval Status

There is no FDA-approved injectable NAD+ drug product. What clinics dispense is prepared by compounding pharmacies for individual patients under a prescription. Compounding is legal in defined circumstances, but a compounded product is not the same as an FDA-approved, FDA-reviewed one — it has not gone through the agency’s evaluation of safety, efficacy, and manufacturing.

The FDA Bulk-Substance (503A) Review — What Actually Happened

NAD+ has a specific and important regulatory history. When it was evaluated for the 503A Bulks List — the list of bulk drug substances pharmacies may compound with — the FDA’s Pharmacy Compounding Advisory Committee (PCAC) reviewed it and it did not earn a favorable path onto that list. A central reason was stability: NAD+’s pyrophosphate linkage is susceptible to breakdown from heat, changes in pH, and light, and the solid is hygroscopic, making the substance prone to degradation. The FDA subsequently proposed that NAD+ not be included on the 503A bulks list. In plain terms, NAD+ effectively did not clear that bulk-substance review, largely over stability and degradation concerns — a fact that is often glossed over in marketing but that patients deserve to know. This is a regulatory and manufacturing judgment, not a statement that NAD+ is dangerous, but it does underscore that injectable NAD+ sits outside the FDA-approved framework.

Compounded NAD+ and Sourcing

Because of this landscape, the regulatory picture for compounded NAD+ can shift, and sourcing matters enormously. A supervised clinic works through licensed compounding pharmacies that handle a fragile molecule correctly — proper manufacturing, storage, and dating — rather than relying on the internet. What is available and appropriate is a moving target that a qualified prescriber is positioned to navigate.

“Research Use Only” Labeling and the Gray Market

Vials sold directly to consumers online are often labeled “for research use only” or “not for human consumption.” That labeling reflects that the product has not been manufactured, tested, or released to the standards required for human injection — purity, sterility, endotoxin levels, actual identity, and (given NAD+’s instability) whether it has already degraded are all unverified. BHRC does not sell or endorse research-vendor NAD+. The responsible path is a supervised clinical program where sourcing, dosing, and monitoring are controlled.

Conclusion

Subcutaneous NAD+ is one of the more popular entries in the wellness and longevity space, and its appeal is understandable: NAD+ is a genuinely fundamental molecule, it declines with age, and the SubQ route offers a convenient, lower-intensity alternative to hours-long IV drips. In physician-supervised practice, it is typically started low — around 20–50 mg — and titrated toward 50–100 mg given one to three times per week, sometimes after a short 100–200 mg daily loading phase, always injected slowly to keep dose- and rate-dependent nausea and flushing in check. But the honest bottom line is that the strongest human evidence in this field belongs to the oral precursors NMN and NR, not to injectable NAD+; that even those studies show raising NAD+ is easier than proving it changes hard outcomes; that NAD+ is not FDA-approved and compounded NAD+ has not been FDA-reviewed; and that NAD+ effectively did not clear the FDA’s bulk-substance review largely over stability concerns. It should never be marketed as an anti-aging cure, a DNA-repair therapy, or an addiction treatment. That combination is exactly why injectable NAD+ belongs inside a supervised medical program — with realistic expectations, careful titration, correct sourcing, and a willingness to stop if it is not delivering value.

Schedule a consultation with Beverly Hills Rejuvenation Center to discuss whether a physician-supervised NAD+ protocol — or a better-established alternative — fits your goals.

Frequently Asked Questions About NAD+ Injection Dosing

What is the standard subcutaneous NAD+ injection dosage?

In physician-supervised practice, subcutaneous NAD+ is usually started around 20–50 mg per injection and titrated toward roughly 50–100 mg, given one to three times per week. There is no FDA-established dose, so these ranges come from clinical use and must be individualized by a prescriber. Injecting slowly and starting low helps limit nausea and flushing.

What is the difference between a loading and a maintenance NAD+ protocol?

A loading phase front-loads exposure — commonly about 100–200 mg daily for 7–10 days, or higher-frequency dosing for the first few weeks — to raise NAD+ availability faster at the start. Maintenance then steps down to about 50–100 mg given weekly or one to two times per week. Loading is optional, carries more side-effect risk, and should only be done under supervision.

How much NAD+ should I inject per day or per week?

Per-injection doses are typically 20–100 mg subcutaneously, and a common weekly maintenance total is roughly 50–200 mg spread across one to three injections. Dividing the weekly amount into smaller doses is often better tolerated than one large injection, because each dose stays under the nausea threshold. Your provider sets the exact amount and frequency.

How do I convert an NAD+ dose from mg to mL?

Volume (mL) = dose (mg) ÷ concentration (mg/mL), and units on a U-100 insulin syringe = mL × 100. At 100 mg/mL, 50 mg is 0.5 mL (50 units) and 100 mg is 1.0 mL (100 units). At 200 mg/mL, 50 mg is 0.25 mL (25 units) and 100 mg is 0.5 mL (50 units). Always read the concentration on your specific vial.

How is subcutaneous NAD+ dosage different from IV dosage?

They are not interchangeable. Subcutaneous doses are small (about 20–100 mg per injection) and absorb gradually, which is gentler on the stomach and cardiovascular system. IV NAD+ delivers much larger amounts (often several hundred to 1,000 mg) infused slowly over one to several hours; a fast IV rate is the classic trigger for nausea and flushing. Only a provider should map one route to the other.

Where do I inject NAD+ subcutaneously?

The most common sites are the abdomen (at least 2 inches from the navel), the outer or front thigh, and the back of the upper arm, with the upper outer buttock as another option. Rotate sites with each injection to reduce irritation and lumps, and avoid skin that is bruised, tender, scarred, or inflamed.

What are the side effects of NAD+ injections?

Most are mild and short-lived: injection-site redness or a brief burning feeling, nausea, flushing or warmth, headache, dizziness, and transient fatigue. Nausea and flushing are dose- and rate-dependent — uncommon at lower doses and more likely if you inject too much too fast. Subcutaneous dosing is generally gentler than a rapid IV. Seek care for signs of allergic reaction, chest symptoms, or an injection-site infection.

Do NAD+ injections actually work — what does the evidence show?

The strongest human evidence is for oral NAD+ precursors (NMN and NR), which reliably raise NAD+ levels and are generally well tolerated, though their effects on hard outcomes are modest and mixed. Controlled evidence specifically for injectable NAD+ is limited, and many reported benefits come from open-label clinic use and self-report. It is best framed as “may support,” not proven, and it is not an anti-aging or disease treatment.

Is injectable NAD+ FDA-approved or legal?

As of 2026, NAD+ is not FDA-approved for any indication, and compounded injectable NAD+ has not been FDA-reviewed. When NAD+ was evaluated for the FDA’s 503A bulk-substance list, it did not earn a favorable path onto that list — largely because of stability and degradation concerns. It is used only via prescription and pharmacy compounding under supervision; online “research-only” vials are not intended for human injection.

Do I need a prescription and medical supervision for NAD+ injections?

Yes. Given its unapproved status, the dose- and rate-dependent side effects, cardiovascular considerations, NAD+’s instability, and the contamination and mislabeling risks of gray-market vials, injectable NAD+ should only be used under a qualified prescriber who controls sourcing, dosing, concentration, and monitoring. BHRC provides physician-supervised programs and does not endorse self-sourced NAD+.

Related Resources / Related Blogs from BHRC

• Schedule a Consultation — start with a physician evaluation for NAD+ or an alternative. (TODO: replace/supplement with the live NAD+ service-page URL once confirmed.)
• MOTS-c Dosage Guide — another metabolism-oriented, injectable compound (verify slug).
• CJC-1295 / Ipamorelin Dosage Guide — growth-hormone-axis peptides (verify slug).
• Tirzepatide Dosage Guide — for patients whose primary goal is metabolic/weight management (verify slug).
• CJC-1295 / Ipamorelin Therapy at BHRC — clinical program page.

References

1. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018;9:1286. PMCID: PMC5876407. Link
2. Nadeeshani H, Li J, Ying T, et al. The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update. (Review of NMN human trials.) PMCID: PMC10721522. Link
3. Systematic review with meta-analysis: Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults. Critical Reviews in Food Science and Nutrition. 2024. doi:10.1080/10408398.2024.2387324. Link
4. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) briefing materials and bulk-substance evaluation for nicotinamide adenine dinucleotide (NAD) — stability/degradation review. Regulations.gov docket FDA-2023-N-0061. Link
5. U.S. Food and Drug Administration. Amendments to the List of Bulk Drug Substances That Can Be Used to Compound Drug Products Under Section 503A (NAD proposed not to be included). Federal Register. 2019. Link

Note on evidence: several widely cited “NAD+” findings — including that NMN and NR roughly double circulating NAD+ within about two weeks — come from studies of oral precursors, not injectable NAD+. This guide cites verified sources for the precursor and regulatory claims and, where a specific identifier could not be confirmed, describes the finding in text without inventing one.

Author and Medical Reviewer

Author — Sam Brooks. Sam is a health content writer at Beverly Hills Rejuvenation Center specializing in evidence-based peptide, hormone, and regenerative-medicine education.

About the medical review: This guide was reviewed by the clinical team at Beverly Hills Rejuvenation Center — board-certified physicians and licensed medical providers who oversee BHRC’s medical protocols and review its clinical education for accuracy, safety, and compliance. Reviewed July 24, 2026. This content is educational and does not replace an individual medical evaluation; peptide therapy at BHRC is physician-supervised.